Objectives: COVID-19 outcomes in population with systemic autoimmune diseases (SAD) remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 infection in people with rheumatic disease.
Methods: Two phases cross-sectional survey of individuals with rheumatic disease in April 2020 and October 2020.